Aesthetic Breast Surgery Updates
On this page you can find the latest updates relating to aesthetic breast surgery
The Royal Colleges of Surgeons of England, Edinburgh, Glasgow and Ireland have published a code of conduct for surgeons performing cosmetic surgery. The purpose of this document is to create a cross-specialty Code of Conduct that sets out the acceptable behaviours expected of all surgeons undertaking cosmetic or aesthetic practice, within the context of the GMC’s Guidance for Doctors (2016), in order, to ensure the highest standards of clinical care and ethical practice. Surgeons seeking certification by the Intercollegiate Cosmetic Surgery Certification Scheme are required to formally accept and agree to abide by the requirements set out in this document. The Code of Conduct aims not only to promote individual good practice but to encourage the creation of professional relationships, networks, and communities to share good practice, discuss complex cases and address the risk to patients from surgeons working in isolation from their peers.
To view the code of conduct please click here
This booklet is for those looking for more information about breast augmentation (breast enlargement). It aims to give an overview of options available, what is involved and the expected outcomes. It will also go through the possible problems associated with breast augmentation and breast implants. There are also links to other resources.
The guide is designed to be used alongside discussions with your surgeon, GP, family and friends to help you in making decisions.
Please find the guide here.
This statement follows the Safety communication released by the FDA on 31st March 2021.
please read the statement here
On the 17th January 2020 the MHRA released an updated statement on the symptoms sometimes referred to as Breast Implant Illness (BII). This clarifies their current position on this issue and outlines their ongoing work in this area.
The statement can be read here
The statement encourages anyone experiencing symptoms they believe to be associated with their breast implants to speak to their surgeon and to report to the MHRA via the Yellow Card scheme
On the 25th November 2019 ABS, BAAPS and BAPRAS issued a joint statement regarding breast implant safety. To view the statement please click here
In June 2019 Jones et al published a paper in Histopathology entitled Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathologic diagnosis and management
NHS Improvements have produced a patient information leaflet, Evidence Based Interventions: Surgery for Breast Reduction
The FDA have released a statement on breast implants following their recent public advisory committee meeting held in March 2019. This is available here for information.
There are a growing number of women who believe that they have a condition, which they have called Breast Implant Illness. This condition consists of a very broad range of non-specific symptoms such as hair loss, brain fog, general fatigue, fibromyalgia, ME, irritable bowel syndrome, skin conditions, lupus, rheumatoid, SLE, Reynaud’s.
ABS members will be aware that the CE mark for Allergan Biocell textured implants has recently not been reinstated. A sample letter [updated November 2019] is available, which members may wish to use when responding to patients, who have implants in situ, to give them further information.
ABS, BAPRAS and the British Society of Breast Radiology have collaborated to produce these guidelines to help surgeons manage patients before and after aesthetic breast procedure. The guidance is based on review of published evidence and, where this is available, a consensus between imaging and surgical specialists. The guidance pertains to all aspects of aesthetic surgery.
To view the guidance please click here